Can Oral Gildeuretinol Slow Advanced Macular Degeneration? - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.

  • By

  • Andrea Surnit

  • July 20, 2026

  • 3 min

Share

Clinical Report: Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Overview

Oral gildeuretinol acetate did not significantly slow geographic atrophy progression compared to placebo in patients with age-related macular degeneration.

Background

Geographic atrophy secondary to age-related macular degeneration is a leading cause of vision loss in older adults. Effective treatments are needed to slow disease progression.

Data Highlights

No statistically significant difference in geographic atrophy lesion growth was observed between gildeuretinol and placebo groups.

Key Findings

  • The primary endpoint of reduced geographic atrophy lesion growth was not met.
  • Gildeuretinol showed a 13% reduction in lesion growth compared to placebo, which was not statistically significant.
  • In a sensitivity analysis, lesion growth reduction was 15% with gildeuretinol.
  • Patients on gildeuretinol experienced less decline in low-luminance visual acuity compared to placebo.
  • Quality of life, as measured by the VFQ-25, improved in the gildeuretinol group.
  • Safety profiles were similar between treatment groups, with no new safety signals identified.

Clinical Implications

The findings indicate that gildeuretinol did not meet its primary efficacy endpoint.

Conclusion

The study indicates that oral gildeuretinol acetate did not achieve its primary endpoint.

Related Resources & Content

  1. Gildeuretinol Acetate vs Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The SAGA Randomized Clinical Trial - PubMed
  2. retinal physician — Oral Gildeuretinol Slows Stargardt Progression
  3. Retinal Physician — Oral Drug Slows GA Progression in Study
  4. Retinal Physician — Supplements Slow Geographic Atrophy Progression
  5. Ophthalmology Management — Study Finds Supplements May Not Slow GA Growth
  6. Oral Gildeuretinol Slows Stargardt Progression
  7. Oral Drug Slows GA Progression in Study
  8. Supplements Slow Geographic Atrophy Progression
  9. Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
  10. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - ScienceDirect
  11. Gildeuretinol Acetate vs Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The SAGA Randomized Clinical Trial - PubMed

Original Source(s)

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

  • by Andrea Surnit

  • July 20, 2026

Related Content

Robust and reproducible population receptive field mapping in patients with retinal pathologies

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.